Alzheimer’s

Health and Human Services Secretary Xavier Becerra came under fire Wednesday during a Senate Finance Committee meeting regarding the Centers for Medicare & Medicaid Services’ restrictive national...

Rural nursing home residents reap benefits from mental healthcare through video … NIH: Prior COVID-19 infection dampens response to vaccination … Skirting cholesterol targets raises CV events by 44...

The cost of 30-day readmission and total 30-day episode costs are higher for patients with Alzheimer disease and related dementias, researchers report.

The Alzheimer’s Association is lobbying lawmakers to convince the Biden administration to reconsider a decision not to provide full coverage for new Alzheimer’s drugs which the organization believes...

Clinicians are not proactive in engaging patients on the subject of memory concerns, missing a key chance for timely diagnosis and early treatment, finds an Alzheimer’s Association report released...

The Alzheimer’s Association and others have strongly criticized a decision by CMS to stand by its highly restrictive coverage for new dementia drugs.

Decisions on administering as-needed antipsychotic drugs require balancing regulatory goals with resident-centered practices, researchers say.

The Food and Drug Administration late last week denied Ely Lilly’s request for expedited approval of the Alzheimer’s drug donanemab, citing the need for more clinical trials to test the safety and...

Share of adults with long COVID symptoms declining … FDA approves new drug Leqembi to treat early Alzheimer’s disease … 1 in 4 adults with chronic pain trying cannabis for relief

The Food and Drug Administration has approved the experimental Alzheimer’s drug Leqembi (lecanemab-irmb) for clinical use in patients with early disease.